Juventas Cell Therapy Announces the Approval of Its First Cell Therapy Product - Inaticabtagene Autoleucel by China NMPA
Juventas Cell Therapy Ltd. announces China National Medical Product Administration (NMPA) has approved its New Drug Application (NDA) for Inatic...
Inaticabtagene Autoleucel Inaticabtagene Autoleucelis Wang Jianxiang Lyv Lulu Juventas Cell Therapy Ltd China National Medical Product Administration
Source: businessinsider.com